BACKGROUND: Early integration of palliative care for patients with metastatic lung cancer improves their quality of life and survival and reduces the aggressiveness of care near the end of life. This study examined the association between the timing of palliative care needs reporting and the aggressiveness of end-of-life care. METHODS: This retrospective cohort study used the French National Hospital Registry to identify all hospitalized adults (20 years old) who died of metastatic lung cancer in France between 2010 and 2013. It compared the use of care and treatments near the end of life as a function of the timing of the first reporting of palliative care needs. The use of chemotherapy and the use of invasive ventilation were defined as primary outcomes. Propensity score weighting was used to control for potential confounders. RESULTS: Among a total of 64,950 deceased patients with metastatic lung cancer, the reporting of palliative care needs was characterized as timely (from 91 to 31 days before death) for 26.3%, late (from 30 to 8 days before death) for 31.5%, and very late (from 7 to 0 days before death) for 12.8%. Palliative care needs were not reported for 19,106 patients (29.4%). Patients with timely reporting of palliative care needs had the earliest and most progressive decrease in the use of anticancer therapy. The use of invasive ventilation also increased with a delay in palliative care needs reporting. CONCLUSIONS: There is a clear association between the timing of palliative care needs reporting and the aggressiveness of care near the end of life. Cancer 2018;124:3044-51. V C 2018 American Cancer Society.
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths worldwide and accounts for 1.7 million deaths annually (ie, 20% of all cancer-related deaths). 1 Lung cancer has also been the most studied clinical model of early palliative care. The 2010 publication of the first randomized controlled trial showing a benefit of early palliative care integrated within standard oncology practice for patients with newly diagnosed metastatic non-small cell lung cancer has brought considerable attention and is widely considered to be the starting point of a paradigm shift. 2, 3 Other randomized clinical trials have confirmed that the early integration of palliative care improves patient and caregiver outcomes, results in more appropriate referral to hospice, and leads to less aggressive care near the end of life. [4] [5] [6] [7] In 2012, an expert consensus organized by the American Association of Clinical Oncology concluded that early palliative care should become the gold standard for the management of patients with advanced cancer. 8, 9 At the same time, taking advantage of the Choosing Wisely campaign, the American Association of Clinical Oncology recommended that cancer-directed therapy be avoided for patients with advanced cancer and an altered performance status and that treatment discontinuation be systematically accompanied by appropriate palliative care. 9 These guidelines were recently updated, 10 and their main components are at the core of the European Society for Medical Oncology's official position on palliative and supportive care. 11 Yet, despite high-quality evidence showing that the provision of palliative care at all stages of the disease (from the time of diagnosis to the end of life) is beneficial for patients, the integration of palliative care into daily oncology practice remains insufficient. Referrals to specialized palliative care teams occur late in the illness trajectory, and only a minority of patients have access to inpatient palliative care units or home-based palliative care services before the very end of life. 12, 13 Barriers to initiating palliative care early during the course of the disease are well known. The lack of time to engage in end-of-life discussions, the fear of taking away patients' hope by mentioning goals of care beyond a cure, the uncertainty surrounding prognosis and survival, and the lack of communication skills get in the way of the better integration of palliative care into oncology. [14] [15] [16] [17] Moreover, as the disease progresses and the situation worsens, both physicians and patients tend to overestimate the probability that anticancer therapies will provide a clinically meaningful benefit and to underestimate the probability that they may have harmful consequences. 18 Oncologists have a critical role in setting the timing of palliative care referral and in choosing the best therapeutic option to avoid overly aggressive care near the end of life.
Previous studies have reported an association between palliative care referral and aggressiveness of care during the final weeks before death. [19] [20] [21] [22] [23] [24] [25] However, these investigations have most often been based on small, select samples of cancer patients, and none have specifically compared variations in the intensity of treatments with respect to the timing of palliative care identification. Our study was aimed at measuring the relation between the identification of palliative care needs at different time points (from 3 months to 1 week before death) and the receipt of aggressive care near the end of life in a large cohort of hospitalized patients with metastatic lung cancer.
MATERIALS AND METHODS

Study Design and Data Source
This is a retrospective cohort study based on routinely collected data. Methods have been described elsewhere. 24 In brief, we constructed a cohort of patients with lung cancer who died during hospitalization; we used data from the French National Hospital Registry (Programme National de M edicalisation des Systèmes d'Information), which prospectively collects demographic, administrative, medical, and economic information about every patient admitted to inpatient or outpatient care units in France. The registry covers 100% of hospital facilities because it has served as the basis for the activity-based hospital payment system since 2005. Admissions and discharges are dated and coded with each patient's unique identifiers, and this allows chronological linkage of the patient's electronic records during a defined period of time. Diseases are coded according to International Classification of Diseases, Tenth Revision (ICD-10), whereas treatments and procedures performed during hospital stays or outpatient visits are reported with a national classification system.
Study Population
We included all hospitalized adult patients (20 years) who died of metastatic lung cancer (ICD-10 code C34 in combination with ICD-10 codes C78 and C79) between January 1, 2010, and December 31, 2013. Patients were excluded from the study population if they were 0 to 19 years old, if they had no formally diagnosed metastases, if they had co-occurring primary malignancies affecting other organs, or if they died in overseas French territories.
Exposure
We considered the time at which palliative care needs were first reported over the course of the last 3 months of life as the main exposure. In France, hospital physicians can report a patient's need for palliative care with the ICD-10 code Z515. This diagnosis code indicates that patients require care and treatments of a palliative nature in relation to an advanced and potentially life-threatening disease. Reporting of this ICD-10 code is required for activity-based payment of palliative care, and it serves to increase the value of diagnosis-related groups used by the National Health Insurance to calculate the reimbursement of hospital stays. For the purpose of this study, we categorized the period of time when palliative care needs were first reported into 4 groups: timely (from 91 to 31 days before death), late (from 30 to 8 days before death), very late (7 to 0 days before death), and none (no reporting of palliative care needs).
Outcomes
Two primary outcomes were used as proxies to evaluate the aggressiveness of care throughout the last 3 months before death: 1) the intravenous or oral administration of chemotherapy and 2) the use of mechanical invasive ventilation. Both outcomes were captured in hospital registry data, which covered all inpatient and outpatient procedures performed within hospital facilities as well as treatments dispensed by hospital-at-home services. Treatments delivered by community pharmacies (eg, oral target therapy in ambulatory care) were not included in our data.
These primary outcomes were completed by a series of secondary outcomes describing various procedures indicative of potentially overly aggressive care near the end of life. 20, 25 We examined whether during the last month before death patients received radiation therapy, blood transfusions, noninvasive ventilation, or hemodynamic support, whether cardiopulmonary resuscitation was attempted, whether patients underwent dialysis (by hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration), and whether they eventually died in intensive care units.
Covariates
Individual characteristics were extracted from the national hospital registry; they included sex, age, location of distant metastases, year of death, and number of comorbidities (calculated as the number of chronic diseases included in the Charlson Comorbidity Index score 26 and reported over the course of the last 3 months of life, with cancer-related conditions excluded). We also considered the type of hospital facility in which death occurred.
Statistical Analysis
We used propensity score weighting to estimate the effect of the timing of palliative care needs reporting on the utilization of aggressive care at the end of life. Propensity score techniques cover a range of statistical tools used in observational (ie, nonrandomized) studies to reduce bias in estimating treatment effects. 27 This is a 2-step process. First, the probability for each patient to receive the intervention of interest is calculated through multivariate logistic regression models. Second, this probability (called the propensity score) is used to match, stratify, or weight the individuals to balance covariates across the different subgroups of the study population and thereby remove measurable confounders. In the current study, we used the inverse probability of treatment weighting method. [28] [29] [30] After calculating the probability of being identified with palliative care needs at different times for each patient Original Article
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Cancer (adjusting for the sex, age, location of distant metastases, number of comorbidities, category of hospital, year of death, and geographic region of residence), we computed weights as the inverse of the propensity score for each individual patient (1/P). The balance of covariates after propensity score weighting was assessed with Pearson's chisquare test. We compared the propensity score-weighted proportion of patients receiving chemotherapy and invasive ventilation according to the timing of palliative care needs reporting, and we graphically represented the changes in chemotherapy and invasive ventilation use over time. Logistic regression models were then fitted to measure the association between the timing of palliative care needs reporting and the likelihood of receiving aggressive treatments during the last month before death. Odds ratios and their 95% confidence intervals accounted for propensity score weighting. Several sensitivity analyses were performed to test the robustness of our approach. First, we excluded the region of residence from the list of independent variables for the calculation of propensity scores. Second, we compared estimates provided by inverse probability of treatment weighting with estimates drawn from propensity score-matched random samples of 2000 individuals.
Ethical Approval
This study was reviewed and approved by the French National Data Protection Agency (decision DE-2014-112) and by the French National Observatory on End-of-Life Care. In accordance with French regulations, no additional ethical review was required because of the nature of the data collection (a noninterventional study using irreversibly de-identified data related to deceased individuals).
RESULTS
Timing of Palliative Care Needs Reporting
A total of 64,950 hospitalized patients who died of metastatic non-small cell lung cancer were included in the Aggressiveness of End-of-Life Care/Goldwasser et al
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July 15, 2018 study (Fig. 1) . The reporting of palliative care needs was timely (from 91 to 31 days before death) for 26.3% of the patients, late (from 30 to 8 days before death) for 31.5%, and very late (from 7 to 0 days before death) for 12.8%. Overall, 19,106 patients (29.4%) had no palliative care needs reported. Compared with patients with timely reporting of palliative care needs, those with late, very late, and no reporting were more often men, less frequently had brain metastases, and died in higher proportions in tertiary hospital facilities or private for-profit hospitals (Supporting Table 1 ). After propensity score weighting, the individual characteristics of patients were balanced across the different groups (Table 1) .
Change in the Use of Chemotherapy and Invasive Ventilation
Between the third month and the final week before death, the probability of receiving chemotherapy decreased from 33.2% to 8.6% among patients with timely reporting of palliative care needs and from 28.7% to 13.8% among patients who had no palliative care needs reported near the end of life ( Fig. 2A) . Among patients who received chemotherapy during the third or second month before death, the proportion of those who continued chemotherapy throughout the final month of life varied from 37.5% to 49.4% to 55.4% for patients with timely or late, very late, and no reporting of palliative care needs, respectively (P < .001). However, although earlier reporting of palliative care needs was associated with an earlier decrease in the use of chemotherapy, it was not associated with the lowest probability of receiving chemotherapy during the final week of life. Among patients whose palliative care needs were not reported, the use of mechanical invasive ventilation increased by more than 10 times over the course of the last 3 months of life, from 0.7% to 7.5% ( Fig. 2B and Supporting Table 2 ).
Association Between the Timing of Palliative Care Needs Reporting and the Receipt of Aggressive Care During the Final Month of Life
Compared with patients with timely reporting of palliative care needs, those with late or very late identification of their palliative care needs were more likely to receive aggressive treatments during their final month of life (Table 2 ). Chemotherapy and invasive ventilation as well as hemodynamic support and dialysis were more common in the absence of timely reporting of palliative care needs (Supporting Table 3 ). The odds of dying in intensive care units were also dramatically increased (odds ratio, 8.94; 95% confidence interval, 7.65-10.44). Sensitivity analyses produced very similar results. Excluding the region of residence from the calculation of propensity scores did not change the findings. This suggests that the association between the reporting of palliative care needs and the likelihood of receiving aggressive treatments at the end of life was not confounded by geographical areas. Second, when we compared the main analysis (based on propensity score weighting) with estimates calculated on the basis of propensity score-matched random samples of 2000 individuals, we found no statistically significant differences (data available upon request).
DISCUSSION
The current study shows a clear association between the timing of palliative care reporting by the oncologist and the aggressiveness of care near the end of life. These results were obtained from a nationwide cohort of hospitalized patients who died of metastatic lung cancer. Our findings suggest that the earlier palliative care needs are identified, the earlier the proportion of patients receiving Our results are in line with previous studies. In the secondary analysis of a randomized controlled trial comparing early palliative care integrated within standard oncology care and standard oncology care alone, 2 Greer et al 31 showed that patients who received early palliative care were 2 times less likely to receive chemotherapy during the last 2 months before death and had a longer delay between the last dose of chemotherapy and death. In a retrospective cohort of 136 patients who died of gynecologic cancer between 2010 and 2012, Zakhour et al 32 showed that earlier end-of-life care discussions were associated with less aggressive measures afterward. In another retrospective study of 100 patients with gynecologic cancer, timely palliative medicine consultation (defined as exposure to inpatient consultation 30 days before death) was associated with less aggressive care interventions at the end of life and reduced direct hospital costs. 33 Hui et al 34 also found that earlier palliative care referral (>3 months before death) was associated with fewer emergency room visits, fewer hospitalizations, and fewer hospital deaths. Beyond their consistency with previous reports, the findings presented in this article shed light onto several issues that ought to be further discussed. The need for palliative care remained undetected for almost one-third of the patients (29%) with metastatic lung cancer who died in hospitals. This is worrisome because it denotes a complete lack of consideration for palliation in the terminal phase of a disease known for its dreadful prognosis. This illustrates the persistent barriers to the integration of palliative care within standard oncology practice. 35 Among these patients with no reported palliative care needs, the goals of care are never questioned, and the final weeks of life are shaped by an intense medicalization in which any physiological abnormality is capable of triggering a technical response despite abundant evidence that overtreatment does more harm than good.
There seem to be two distinct patterns in the behavior of oncologists facing the progression of metastatic lung cancer and the necessity of addressing palliative care needs as the end of life approaches. The identification and formal reporting of palliative care needs before the last month of life are compatible with advanced care planning and with the limitation of overly aggressive treatments. At this time, the integration of a palliative care team into the decision-making process regarding treatments is still possible, changes in the goals of care have a chance to influence the trajectory of patients, and supportive measures are more likely to improve quality of life. Moreover, timely reporting of palliative care needs allows a progressive reduction of aggressive treatments. In contrast, reporting of palliative care needs during the final month of life is too late to be optimal. Although it is still compatible with the limitation of active treatments, it occurs too late to anticipate home-based palliative care, and it comes at the price of a more sudden discontinuation of anticancer agents. This timing is typical of the old model of palliative care, in which palliative measures are initiated only when oncologists have no further chemotherapy options. This leads to restricting palliative care to the very end-of-life stage with a sequential intervention of oncologists and palliative care teams, which offers less time for coping. We found that although patients whose palliative care needs were reported before the last month of life had the earliest and most progressive decrease in anticancer treatments, it did not prevent some patients from receiving chemotherapy during the last week before death. Indeed, a palliative care status and chemotherapy prescription are not contradictory because chemotherapy may be palliative in certain situations. Palliative care teams have an expert role in facilitating an ethical decision-making process, especially with respect to the discontinuation of anticancer therapies.
Because time is a critical parameter, any improvement in the early identification of palliative care needs may reduce the aggressiveness of care at the end of life. Our results invite physicians to regularly question the goal of care and to explicitly specify whether the aim of treatments is to cure the disease, prolong survival with the disease, or exclusively palliate symptoms. This clarification not only is necessary to foster cooperation between oncologists and specialist palliative care teams but also empowers patients to make informed treatment decisions. Most patients with incurable cancer do not clearly understand that the intent of the chemotherapy is not a cure. 36 For oncologists who already tend to identify palliative care needs early, a simple recommendation would be to document changes in the goals of care throughout the course of the disease in a patient's medical records. They would improve their practice by introducing specialist palliative care consultants earlier and by better anticipating clinical complications. Physicians who tend to identify patients' palliative care needs late (ie, during the last month of life) should be invited to participate in specific training programs to help them integrate palliative care into their daily clinical practice and to promote multidisciplinary meetings with specialist palliative care teams. Finally, physicians who seldom identify the palliative care needs of cancer patients near the end of life should avoid solo decision making and should receive adequate training to consider life expectancy evaluations (together with the inherent uncertainty that this suggests), to incorporate patients' wishes and personal preferences into the decision to initiate, continue, or discontinue treatments, and to seek advice from colleagues specialized in palliative care. 28, 29 Our work has several limitations. It is not a randomized study but rather is an observational, registry-based study. Trials investigating the impact of the timing of palliative care introductions are difficult because of the lack of statistical power and ethical concerns. However, the trial conducted by Zimmermann et al 4 supported early palliative care for patients with advanced cancer and showed the feasibility of the method using cluster randomization in this setting. A second limitation of our work is that early palliative care should ideally start at the time of diagnosis and should not be limited to the last 3 months of life. From our data set, we could not determine how many patients were identified with palliative care needs at the time of diagnosis. Earlier identification is expected to be associated with even better results. 37 Moreover, it should be noted that our study aimed to evaluate not the impact of the provision of palliative care but rather the effect of earlier or later identification of palliative care needs. Although most patients formally reported as being in need of palliative care are expected to receive such care, it is possible that some patients were identified very close to death and did not survive long enough to actually receive palliative care. A third limitation is that new therapeutic options have appeared, including targeted therapies and immunotherapies, which add uncertainty and complexity to the decision making in advanced disease. 38 In conclusion, our findings supplement the conclusions of previous randomized controlled trials of early palliative care, and they show that time is a critical parameter. Any improvement in earlier identification is associated with reduced aggressiveness of care at the end of life. Delaying the identification of palliative care needs can have detrimental effects on a patient's trajectory. Altogether, these results have the potential to improve current practice and help us to tailor adequate strategies to better integrate palliative care into mainstream oncology.
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